Pressure BioSciences, Inc. (PBI), a life sciences company, engages in the research, development, and commercialization of sample preparation system. It focuses on the development of a platform technology, called pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The Company offers Barocycler instrument and an internally developed disposable PULSE (Pressure Used to Lyse Samples for Extraction) Tubes, which together make up the PCT sample preparation system.
Type | Public | |
Founded | 2004 | |
HQ | Easton, MA, US | Map |
Website | pressurebiosciences.com |
USD | |
---|---|
Revenue (Q3, 2020) | 533.9k |
Gross profit (Q3, 2020) | 286.8k |
Gross profit margin (Q3, 2020), % | 53.7% |
Net income (Q3, 2020) | (3.3m) |
EBIT (Q3, 2020) | (818.8k) |
Market capitalization (26-Feb-2021) | 8.9m |
Closing stock price (26-Feb-2021) | 2.3 |
Cash (30-Sept-2020) | 94.8k |
EV | 23.0m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 190.7k | 280.4k | 305.7k | 324.9k | 297.9k | 370.7k | 357.7k | 420.8k | 404.1k | 307.5k | 372.5k | 440.1k | 413.1k | 580.3k | 510.5k | 511.0k | 535.3k | 551.4k | 540.4k | 646.1k | 610.8k | 639.0k | 521.8k | 510.2k | 518.7k | 501.2k | 253.9k | 268.2k | 533.9k |
Cost of goods sold | 108.7k | 175.2k | 209.8k | 221.7k | 243.1k | 262.9k | 236.0k | 287.3k | 328.7k | 324.8k | 270.0k | 234.3k | 309.7k | 304.2k | 285.8k | 175.1k | 134.9k | 247.0k | |||||||||||
Gross profit | 189.2k | 237.9k | 370.5k | 288.8k | 267.9k | 272.4k | 315.4k | 253.1k | 317.3k | 286.0k | 369.0k | 287.4k | 200.5k | 214.5k | 215.4k | 78.7k | 133.3k | 286.8k | |||||||||||
Gross profit Margin, % | 64% | 58% | 64% | 57% | 52% | 51% | 57% | 47% | 49% | 47% | 58% | 55% | 39% | 41% | 43% | 31% | 50% | 54% |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Cash | 222.8k | 1.5k | 31.4k | 473.9k | 116.8k | 138.4k | 81.0k | 103.1k | 29.6k |
Accounts Receivable | 269.2k | 216.3k | 147.6k | 272.0k | 113.3k | 206.8k | 474.8k | 229.4k | |
Prepaid Expenses | 143.6k | 83.4k | 85.6k | 104.2k | 213.9k | 214.7k | 170.7k | 213.5k | |
Inventories | 1.1m | 923.4k | 736.7k | 850.6k | 1.0m | 258.1k | 857.7k | 765.5k | 617.7k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 234.4k | 297.0k | 15.5k | 20.9k | 50.3k | 167.9k | 113.7k | 66.7k | 428.5k | 9.4k | 98.2k | 220.3k | 38.2k | 76.9k | 93.4k | 71.6k | 41.9k | 121.4k | 201.3k | 18.7k | 81.2k | 18.5k | 5.9k | 269.7k | 117.9k | 135.4k | 31.8k | 41.5k | 94.8k |
Accounts Receivable | 159.0k | 115.0k | 204.0k | 241.7k | 294.9k | 278.0k | 314.2k | 200.9k | 178.4k | 190.7k | 335.0k | 323.4k | 350.0k | 362.8k | 393.9k | 511.1k | 589.7k | 518.7k | 564.0k | 548.3k | 322.6k | 526.1k | 374.3k | 443.2k | 410.6k | 411.4k | 120.9k | 121.3k | 330.5k |
Prepaid Expenses | 80.4k | 128.3k | 269.8k | 374.6k | 510.4k | 103.7k | 53.4k | 61.0k | 229.0k | 157.6k | 120.1k | 127.0k | 151.5k | 74.4k | 337.5k | 145.0k | 180.0k | 207.7k | 175.9k | 146.3k | 199.3k | 202.7k | 254.5k | 183.3k | 127.7k | 239.2k | 203.9k | 192.6k | 159.7k |
Inventories | 1.1m | 1.1m | 1.0m | 975.9k | 905.7k | 890.9k | 866.6k | 851.5k | 786.8k | 853.2k | 852.5k | 799.0k | 783.9k | 808.8k | 966.5k | 1.0m | 1.0m | 940.4k | 1.1m | 1.1m | 892.4k | 900.1k | 899.9k | 753.1k | 744.8k | 713.9k | 655.8k | 614.9k | 516.2k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (3.0m) | (3.5m) | (4.1m) | (4.6m) | (7.4m) | (2.7m) | (10.7m) | (9.7m) | (11.7m) |
Depreciation and Amortization | 141.3k | 107.5k | 79.6k | 65.7k | 25.3k | 17.9k | 8.6k | 94.3k | 123.6k |
Inventories | 48.6k | 95.7k | 186.7k | (113.9k) | (187.8k) | 133.1k | (112.0k) | (56.1k) | 78.8k |
Accounts Payable | 763.8k | 309.2k | (97.1k) | (67.0k) | (94.4k) | (534.1k) | 182.0k | 69.6k | 156.9k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (1.6m) | (2.2m) | (1.1m) | (1.6m) | (2.4m) | (779.4k) | (1.8m) | (2.5m) | (1.8m) | (2.4m) | (3.3m) | (2.0m) | (2.8m) | (3.4m) | (6.0m) | (5.0m) | (5.9m) | (5.6m) | (6.2m) | (7.9m) | (2.2m) | (4.5m) | (6.3m) | (2.1m) | (4.8m) | (8.0m) | (4.0m) | (8.5m) | (11.8m) |
Depreciation and Amortization | 77.0k | 109.5k | 29.3k | 57.2k | 82.4k | 21.5k | 40.4k | 63.0k | 19.6k | 39.7k | 59.4k | 6.9k | 12.2k | 18.3k | 6.2k | 12.3k | 15.5k | 2.5k | 4.7k | 7.0k | 23.5k | 45.9k | 70.7k | 23.6k | 47.2k | 68.8k | 45.0k | 74.2k | 103.4k |
Inventories | (29.8k) | (4.1k) | 47.7k | 93.1k | (163.4k) | 32.5k | 56.7k | 71.9k | (50.1k) | (116.5k) | (115.8k) | 51.6k | 66.7k | 41.7k | 71.8k | 36.0k | 30.2k | (35.1k) | (226.2k) | (217.5k) | (14.8k) | (2.5k) | (2.4k) | 12.3k | 20.7k | 51.6k | (38.1k) | 2.9k | 101.5k |
Accounts Payable | 276.5k | 537.2k | 238.8k | 304.9k | 399.1k | (140.5k) | (116.6k) | 1.9k | (90.0k) | 59.3k | (17.0k) | (115.7k) | (56.3k) | (201.0k) | (161.3k) | (51.5k) | (409.2k) | 265.5k | 338.8k | 445.9k | 51.8k | 108.7k | 16.4k | (184.4k) | 152.3k | 838.3k | 54.5k | (5.9k) | (109.4k) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 4.5 x |
Pressure BioSciences has 1.18k Twitter Followers. The number of followers has decreased 0.1% month over month and decreased 0.4% quarter over quarter
When was Pressure BioSciences founded?
Pressure BioSciences was founded in 2004.
Who are Pressure BioSciences key executives?
Pressure BioSciences's key executives are Richard T. Schumacher, Jeffrey N. Peterson and Edmund Ting.
How many employees does Pressure BioSciences have?
Pressure BioSciences has 17 employees.
What is Pressure BioSciences revenue?
Latest Pressure BioSciences annual revenue is $1.8 m.
What is Pressure BioSciences revenue per employee?
Latest Pressure BioSciences revenue per employee is $106.5 k.
Who are Pressure BioSciences competitors?
Competitors of Pressure BioSciences include REMSleep Holdings, ControlRad Systems and Cerevast Therapeutics.
Where is Pressure BioSciences headquarters?
Pressure BioSciences headquarters is located at 14 Norfolk Ave, South Easton, Easton.
Where are Pressure BioSciences offices?
Pressure BioSciences has offices in Easton and Medford.
How many offices does Pressure BioSciences have?
Pressure BioSciences has 2 offices.
Receive alerts for 300+ data fields across thousands of companies